BioPharmSignal logoBioPharmSignal

Biotech News

Nkarta to Participate in September Investor Conferences

Nkarta (NKTX)NkartaCompany update

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences:

Related news

NKTXNkarta2026-11-06 21:01 EST

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

NKTXNkarta2026-11-05 21:34 EST

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

MGNXMacroGenics2026-11-05 21:05 EST

MacroGenics to Participate in Upcoming Investor Conferences

STROSutro Biopharma2026-11-04 13:00 EST

Sutro Biopharma to Participate in Upcoming Investor Conferences

RLAYRelay Therapeutics2026-11-02 21:05 EST

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

ANGOAngioDynamics2026-10-29 12:00 EST

AngioDynamics to Participate in Upcoming Investor Conferences

RVMDRevolution Medicines2026-10-27 20:05 EST

Revolution Medicines to Participate in November 2026 Investor Conferences

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

FATEFate Therapeutics2026-10-01 11:00 EST

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

IDYAIDEAYA Biosciences2026-11-04 11:00 EST

IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events

View all latest news

Nkarta

Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer. NKX019 NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing. Ntrust Studies Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with...

Recent company news

NKTXNkarta2026-11-06 21:01 EST

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

NKTXNkarta2026-11-05 21:34 EST

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

NKTXNkarta2026-09-10 11:00 EST

Nkarta to Participate in September Investor Conferences

NKTXNkarta2026-09-08 11:00 EST

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

NKTXNkarta2026-08-10 20:24 EST

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

Stock data

Close
1.57 USD
Market cap
208.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States